

## Company Announcement

9 July 2012

## Novo Nordisk A/S – Share repurchase programme

On 2 May 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.8 billion in the period from 2 May 2012 to 7 August 2012.

Since the announcement as of 2 July 2012, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,235,527		1,011,567,877
2 July 2012	36,000	849.79	30,592,577
3 July 2012	35,000	870.06	30,452,044
4 July 2012	36,000	869.62	31,306,262
5 July 2012	35,000	875.77	30,652,087
6 July 2012	38,000	885.59	33,652,545
Accumulated under the programme	1,415,527		1,168,223,392

With the transactions stated above, Novo Nordisk owns a total of 14,524,145 treasury shares, corresponding to 2.6% of the share capital. The total amount of shares in the company is 560,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during a 12 month period beginning 2 February 2012. As of 6 July 2012, Novo Nordisk

Company Announcement no 44 / 2012

Page 1 of 2

has repurchased a total of 9,663,626 B shares equal to a transaction value of DKK 7,866,083,987.

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,000 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media: Investors:

Anne Margrethe Hauge Kasper Roseeuw Poulsen Tel: (+45) 4442 3450 Tel: (+45) 4442 4303 <a href="mailto:knowedge">krop@novonordisk.com</a>

Frank Daniel Mersebach Tel: (+45) 4442 0604 fdni@novonordisk.com

Lars Borup Jacobsen Tel: (+45) 3075 3479 <a href="mailto:lbpj@novonordisk.com">lbpj@novonordisk.com</a>

In North America: Ken Inchausti

Ken InchaustiJannick LindegaardTel: (+1) 609 514 8316Tel: (+1) 609 786 4575kiau@novonordisk.comjlis@novonordisk.com